We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Approaches to Alzheimer's Disease

By Biotechdaily staff writers
Posted on 11 Jul 2005
A study has suggested radical new approaches to the diagnosis and treatment of Alzheimer's disease.

The investigators question the current theory that the dementia in Alzheimer's is caused by plaque deposits in the brain. More...
They argue that, instead, the disease may be caused by a fundamental defect in the brain's ability to configure the newly synthesized proteins that are necessary for memory. They offer evidence that the presence of beta-amyloid, the primary component of the plaque deposits, is only a marker of the dementia, rather than the cause. The study, from the laboratory of Jordan L. Holtzman at the University of Minnesota (Minneapolis, USA), was published in the June 24, 2005, issue of Biochemical Biophysical Research Communications.

The investigators outline several flaws in current approaches that link the disease to the toxicity of the beta-amyloid. They note that longitudinal studies of elderly subjects have shown that up to 40% of those with plaque deposits were not demented at the time of death. Similarly, despite the fact that beta-amyloid is produced in everyone, the deposits are only seen in the elderly. This suggests that the beta-amyloid is bound to carrier proteins, which keep it in solution. The study presents data indicting that Alzheimer's may result from a fundamental failure of the nerve cells to produce these carrier proteins.

Determining the levels of the carrier proteins in the cerebrospinal fluid may be a useful test to diagnose and monitor the disease, according to the researchers. Also, new agents should be developed that enhance the ability of cells to produce functional proteins, such as methoxychlor, shown effective in animal studies. In the meantime, drugs that either block the synthesis of the beta-amyloid or dissolve the plaque have been uniformly unsuccessful in moderating the disease.




Related Links:
University of Minnesota

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
HPV Test
Allplex HPV28 Detection
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.